---
type: "Nootropic"
title: "NMN"
description: "NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established."
resource: "https://nootropikler.com/nootropics/nmn"
tags: ["NAD+", "Aging research", "Cognition research"]
timestamp: 2026-11-11T00:00:00Z
category: "neurotrophic"
source: "semi-synthetic"
latin: "Nicotinamide mononucleotide (NMN) / beta-Nicotinamide mononucleotide"
language: "en"
---

# NMN

*Nicotinamide mononucleotide (NMN) / beta-Nicotinamide mononucleotide*

NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | No established dose for cognitive use |
| Safety | See detailed safety warnings |

> 2026-11-11 correction: Muscle and blood biomarkers were separated from brain benefit and lifespan; the 2026 review was added. Single-dose tolerability was not extrapolated to long-term safety. Unsupported general half-life, personal-protocol and regulatory-approval inferences were removed.

## What is NMN?

NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established.

NMN contributes to NAD+ synthesis through NMNAT. This biochemical pathway does not show that supplementation increases ATP, DNA repair or cognitive performance in the human brain. Cellular and animal findings involving sirtuins and PARP must be distinguished from evidence of slower human aging.

## Clinical Evidence

Yoshino et al. (2021) studied 250 mg/day NMN or placebo for 10 weeks in 25 postmenopausal women with prediabetes and overweight/obesity. Muscle insulin sensitivity improved; muscle NAD+ content did not increase and many other metabolic measures were unchanged. Cognition, dementia prevention and lifespan were not evaluated.

Muscle insulin sensitivity in a selected group of women with prediabetes is not general metabolic improvement in healthy people or increased brain NAD+. Tissue measurements, cognition, dementia prevention and lifespan are distinct outcomes.

Irie et al. (2020) studied single doses of 100, 250 and 500 mg NMN in 10 healthy men over 5 hours. Nicotinamide metabolites rose; this trial did not demonstrate blood NAD+ increases or long-term anti-aging effects.

This single-arm, nonrandomized experiment followed 10 men for 5 hours. Increased metabolites do not establish NMN plasma half-life or long-term safety; increased blood NAD+, slower aging and personal doses cannot be inferred.

Mills et al. (2016) reported improvements in selected age-associated metabolic and physiological measures after 12 months of NMN administration in C57BL/6N mice.

Changes in mouse physiological measures do not establish longer human lifespan or cognitive benefit. This experiment cannot provide a safe human anti-aging protocol.

Yang et al. (2026) included 15 trials, with 10 contributing to safety analyses; follow-up ranged from 14 days to 24 weeks. No clear adverse-event increase was found; significant broad benefits in weight, fasting glucose, HbA1c or lipids were not demonstrated.

The review covers NMN or NMN-related preparations; short follow-up cannot establish rare harms, cancer outcomes or long-term safety. Muscle/blood findings are not cognition or lifespan outcomes; dose ranges are not personal prescriptions or safe upper limits.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

## Safety and Side Effects

No clear harm increase in short, small NMN studies does not establish long-term, pregnancy/breastfeeding or drug-combination safety. Missing interaction records are not evidence of safety; do not change cancer treatment or prescribed medicines on your own.

The FDA’s general supplement guidance explains that supplements are not approved for safety and effectiveness before sale as drugs are. A supplement label does not mean NMN is approved for cognitive effects or anti-aging treatment.

This guidance alone does not establish NMN’s current product- and country-specific legal classification. Regulatory classification, clinical benefit and drug authorization are separate matters; official product records require separate verification.


## Frequently Asked Questions

### What does NMN do and why is it used?

NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established.

### What is the recommended daily dose for NMN?

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

### Are there any side effects of using NMN?

No clear harm increase in short, small NMN studies does not establish long-term, pregnancy/breastfeeding or drug-combination safety. Missing interaction records are not evidence of safety; do not change cancer treatment or prescribed medicines on your own.

### Is NMN legal in Türkiye and where can it be obtained?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### When does the effect of NMN start to be felt?

No established timeframe

## Sources

- Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. *Science*, 372(6547), 1224–1229. [PubMed · PMID 33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/)
- Irie J, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. *Endocrine Journal*, 67(2), 153–160. [PubMed · PMID 31685720](https://pubmed.ncbi.nlm.nih.gov/31685720/)
- Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. *Cell Metabolism*, 24(6), 795–806. [PubMed · PMID 28068222](https://pubmed.ncbi.nlm.nih.gov/28068222/)
- Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. *Journal of the International Society of Sports Nutrition*, 18(1), 54. [PubMed · PMID 34238308](https://pubmed.ncbi.nlm.nih.gov/34238308/)
- Yang W, et al. (2026). Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. *Nutrients*, 18(14), 2251. https://doi.org/10.3390/nu18142251 [PubMed · PMID 42514320](https://pubmed.ncbi.nlm.nih.gov/42514320/)
- US Food and Drug Administration. FDA 101: Dietary Supplements. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements [US Food and Drug Administration](https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements)

## Related nootropics

- [Creatine](/okf/nootropics/creatine.md)
- [Acetyl-L-Carnitine](/okf/nootropics/acetyl-l-carnitine.md)
- [Omega-3 DHA/EPA](/okf/nootropics/omega-3.md)
